


Amendment to the Specification:

**Amendment to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (Cancelled)
2. (Cancelled)
3. (Cancelled)
4. (Cancelled)
5. (Cancelled)
6. (New) A method for decreasing the absorption of phosphate or oxalate in the gastrointestinal tract of an animal, comprising the step of:
  - (a) administering an effective amount of a formulation comprising:
    - i) a pharmaceutically acceptable carrier, and
    - ii) a water-soluble polyether glycol polymer of the formula:



Wherein the polymer has an average molecular weight from about 5,000 to about 750,000 Daltons.

7. (New) A method for decreasing the absorption of phosphate or oxalate from the gastrointestinal tract of an animal which comprises the step of:

(a) Administering an effective amount of a formulation comprising:

i) a pharmaceutically acceptable carrier, and

ii) a water-soluble polyether glycol polymer which comprises: a structural backbone of carbon atoms and oxygen atoms where there are at least two consecutive carbon atoms present between each oxygen atom; a moiety on the backbone of the polymer or a functionalized derivative on the polymer that is cationic at physiological pH and permits complexation with phosphate or oxalate; and an average molecular weight from about 5,000 to about 750,000 Daltons, wherein the polymer is prepared from the process comprising:

1) preparing a polyether polymer by the acid catalyzed polymerization of an epihalohydrin monomer;

2) increasing the molecular weight of the polyepihalohydrin polymer prepared in step 1; and

3) derivatizing the polyether backbone of the polymer with ethylenediamine or diethylenetriamine to form the water soluble polyether glycol polymer.